Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ikena Oncology Inc (NQ: IKNA )

6.770 +0.100 (+1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ikena Oncology Inc

Ikena Oncology to Participate in Upcoming Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces $40 Million Underwritten Offering
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Appoints Owen Hughes as Board Chair
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference
From Ikena Oncology, Inc.
Via Business Wire
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021
From Ikena Oncology, Inc.
Via Business Wire
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
From Ikena Oncology, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.